Finasteride (Propecia): Generic Bioequivalence and Androgenic Alopecia Outcomes

Finasteride occupies an unusual position in dermatologic pharmacotherapy—a systemic agent prescribed primarily for cosmetic indication. Merck's Propecia brand established the 1 mg daily dosing paradigm for male-pattern androgenic alopecia (AGA), demonstrating measurable increases in hair count and diameter over 12-month intervals in pivotal trials. When patent exclusivity lapsed, multiple AB-rated generics entered the US market. The pharmacokinetic question patients actually ask is simpler: does the $12/month generic behave like the $80/month brand?

Under FDA bioequivalence criteria, generic finasteride 1 mg tablets must deliver equivalent AUC and C_max within 80–125% confidence intervals relative to the reference listed drug. Independent dermatology cohort studies report comparable scalp DHT suppression and photographic hair-density scores across major generic manufacturers after 24 months of continuous use. Long-term efficacy, however, is adherence-dependent—finasteride requires sustained daily intake; interruption allows DHT normalization and progressive miniaturization to resume within months.

Adverse event literature merits balanced presentation. Sexual dysfunction (decreased libido, erectile changes) appears in 2–4% of trial participants, with post-marketing reports of persistent symptoms in a minority subset—a contested epidemiological signal requiring further prospective study. Generic availability has dramatically improved price accessibility, yet sourcing from uncertified online vendors introduces tablet-substitution risk (dose inaccuracy, undeclared excipients). Cross-reference our sourcing directory before purchasing any finasteride product outside a licensed US pharmacy.